Facing a second recurrence is incredibly tough, and it makes sense to want to know what's ahead. Cisplatin and doxorubicin is a recognized combination used when prior chemotherapy regimens, like carboplatin and paclitaxel, have already been tried.
Here are some common side effects to be aware of with this combination:
- Show Full Answer
Facing a second recurrence is incredibly tough, and it makes sense to want to know what's ahead. Cisplatin and doxorubicin is a recognized combination used when prior chemotherapy regimens, like carboplatin and paclitaxel, have already been tried.
Here are some common side effects to be aware of with this combination:
- Nausea and vomiting — anti-nausea medications are often given beforehand to help manage this
- Fatigue and shortness of breath
- Hair loss
- Mouth sores
- Increased risk of infection, bruising, or bleeding
- Decreased appetite
One important thing to know is that doxorubicin can affect the heart over time, so the care team will likely monitor heart function closely. The more doxorubicin received, the higher that risk becomes — so don't hesitate to ask about heart monitoring as part of the plan. Given the high-grade serous profile and specific biomarkers, it's also really worth asking the oncologist about immunotherapy options. Drugs like pembrolizumab (Keytruda) combined with lenvatinib (Lenvima), or dostarlimab (Jemperli), have FDA approval for certain endometrial cancer types and may be relevant depending on the full biomarker picture.
Clinical trials are another avenue worth exploring, as newer drug combinations are actively being studied for recurrent cases like this one. The care team can help identify what might be a good fit.
June 15
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
